Truvada should remain first choice for HIV prevention, experts say

In October 2019, the U.S. Food and Drug Administration approved a second medication for use as HIV preexposure prophylaxis, also known as PrEP, sparking controversy about which drug should be prescribed. Gilead Sciences, which manufactures both approved drugs, has argued that the new drug is safer and more effective than the old drug. But these claims are overstated, say a team of clinical and public health experts. Their commentary, "Tenofovir Alafenamide for HIV Preexposure Prophylaxis—What Can We DISCOVER About Its True Value?", appears in the January 14 issue of Annals of Internal Medicine.